

# MARKET REPORT



## Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018

## Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

## Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 5, 24 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline. For more information, visit <https://www.bioportfolio.co.uk/product/214077> or email [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) to order

Kidney Injury) (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Additional Details

**Publisher** : Global Markets Direct

**Reference** : GMDHC10650IDB

**Number of Pages** : 130

**Report Format** : PDF

**Publisher Information :**



**Global Markets Direct**  
The home of leading edge research and analysis

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

# Table Of Contents for Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018 [Report Updated: 17-07-2018]

- Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageAcute Renal Failure (ARF) (Acute Kidney Injury) - OverviewAcute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesAcute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeAcute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics DevelopmentA1M Pharma ABAlloksys Life Sciences BVAm-Pharma BVAngion Biomedica CorpArch Biopartners IncAtox Bio LtdBalmes Transplantation SASCellmid LtdCFM Pharma Holding BVCypralis LtdDURECT CorpEvotec AGExponential Biotherapies IncF. Hoffmann-La Roche LtdGeneScience Pharmaceuticals Co LtdKlotho Therapeutics IncKringle Pharma IncMitobridge IncMitotech SAQuark Pharmaceuticals IncSBI Pharmaceuticals Co LtdSilver Creek Pharmaceuticals IncSpherium Biomed SLSTATegics IncTorrent Pharmaceuticals LtdXigen SA
- Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressANG-4102 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBB-3 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbrimapitide - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBT-0302 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBT-0303 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBT-0401 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCAB-101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCC-4066 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscerium oxide - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresscilastatin - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDrug for Kidney Diseases - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDUR-928 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressEA-230 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressIL-233 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressiron sucrose + Sn protoporphyrin - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressK-1052 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressKP-100IT - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMA-0204 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMetablok - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMG-53 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMTB-2 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPlastomitin - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressQPI-1002 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressR-190 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Alkaline Phosphatase Enzyme Replacement for Acute Kidney Injury - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Klotho Replacement for Kidney Disease, Aging, Breast Cancer, Cognitive Impairment and Type 2 Diabetes - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Protein to Agonize GHR for Growth Failure In Children With Kidney Disease - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressreltecimod sodium - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRLS-003 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRMC-035 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSGF-1 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit HDAC for Acute Kidney Injury - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit PADI4 for Acute Kidney Injury, Hepatic and Pancreatic Injuries - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecules to Inhibit GGT for Acute Renal Injury - Drug ProfileProduct DescriptionMechanism Of

ActionR&D ProgressStem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSTSE-15 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSUL-138 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTRC-160334 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVanadis-03 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAcute Renal Failure (ARF) (Acute Kidney Injury) - Dormant ProjectsAcute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued ProductsAcute Renal Failure (ARF) (Acute Kidney Injury) - Product Development MilestonesFeatured News & Press ReleasesJul 09, 2018: Quark Pharmaceuticals Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac SurgeryMay 29, 2018: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)May 22, 2018: Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For MetablokMay 08, 2018: Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery PatientsMar 21, 2018: Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney InjuryMar 09, 2018: AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney InjuryFeb 27, 2018: Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBioNov 14, 2017: A1M Pharma reports positive results from its GLP toxicology study - now able to finalize application to initiate clinical studiesNov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES ConferenceNov 07, 2017: ROSgard protects bone marrow during radiation treatment - patent application has been filedNov 06, 2017: Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARd Modulators in Acute Kidney Injury at American Society of Nephrology Annual MeetingNov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology MeetingNov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology MeetingOct 27, 2017: A1M Pharma: First company in the world with large scale manufacturing of A1M under full GMP compliance for clinical studiesSep 13, 2017: Patented the first drug that acts as a protector of the kidneyAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer

# How to Buy...

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018 [Report Updated: 17-07-2018]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/214077>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$2000** | Single User Price
- \$4000** | Site License Price
- \$6000** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.